Elanco Animal Health Incorporated Common Stock (ELAN) fair value

ACCE thesis

Elanco makes animal health products, including parasiticides and vaccines for companion animals and livestock, and has built a sizeable franchise around its Credelio and Seresto lines for dogs and cats. The structural case rests on recurring, consumable demand: flea, tick and heartworm treatments are bought every month, which gives the business a sticky revenue base that is less exposed to hospital capital spending. Revenue growth of 10.2% is the headline number, and the forward P/E of 17.4 sits well below where many branded pharma names trade, though the company's 8.6% operating margin and negative ROE show it has not yet converted growth into durable earnings power. The near-term question is whether margins keep expanding as the sales base scales, since a 55.4% gross margin leaves room for improvement if operating costs are controlled. At roughly $11.8B in market cap with no index membership, the name is a candidate for a deeper look at margin trajectory and pipeline execution.